Renal outcomes with sodium glucose cotransporter 2 (SGLT2) inhibitor, dapagliflozin, in obese insulin-resistant model

• المؤلفون الرئيسيون: Krit Jaikumkao, Anchalee Pongchaidecha, Nuttawud Chueakula, Laongdao Thongnak, Keerati Wanchai, Varanuj Chatsudthipong, Nipon Chattipakorn, Anusorn Lungkaphin
• التنسيق: دورية
• منشور في: 2018
• الوصول للمادة أونلاين: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85044715832&origin=inward; http://cmuir.cmu.ac.th/jspui/handle/6653943832/48382
• المؤسسة: Chiang Mai University

© 2018 Elsevier B.V. A growing body of evidence indicates that obesity and insulin resistance contribute to the progression of renal disease. This study was performed to determine the effects of dapagliflozin, a novel sodium glucose cotransporter 2 (SGLT2) inhibitor, on renal and renal organic anion...